Bioavailability Hormones Marketing 
XTalks
FEBRUARY 5, 2025
a clinical-stage biotech company focused on developing next-gen injectable and oral nutrient-stimulated hormone (NuSH) analog peptides for the treatment of obesity, overweight and related conditions, has priced its initial public offering (IPO) at $18.00 Metsera, Inc., per share, raising $275 million in gross proceeds. billion in 2024 to $37.94
Delveinsight
JULY 30, 2020
The global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 In patients with CALD, Adrenoleukodystrophy market offers two therapies, namely Lorenzo’s oil and haematopoietic stem cell transplantation (HSCT) , using either umbilical cord stem cells or bone marrow stem cells.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
JANUARY 7, 2021
The startup recently raised USD 87 million to propel itself in a competitive market. Terns schedules to bring a third candidate into the clinic this year, TERN-501, a thyroid hormone receptor (THR) beta-agonist. Terns raises USD 87 Million for NASH drugs. Ribometrix announces collaboration with Genentech.
XTalks
NOVEMBER 6, 2024
per share, the offering included 1,300,000 ordinary shares, which began trading on the Nasdaq Global Market under the ticker symbol GELS on October 29, 2024. The stable gel matrix holds multiple ingredients, offering targeted release and enhanced bioavailability while optimizing patient experience. Priced at $4.0
XTalks
FEBRUARY 3, 2023
Stemline Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics and a wholly owned subsidiary of the Menarini Group, will market Orserdu in the US. ER+, HER2- Breast Cancer ER+, HER2- cancers account for about 75 percent of breast cancers.
Expert insights. Personalized for you.
59 
Let's personalize your content